The doctor would treat her sickle cell pain crisis — if she promised not to get an abortion

While many sickle cell patients have felt pressure to end a pregnancy, others are pressured to keep a pregnancy.

May 28, 2024 Check out STAT+

Sponsored By

Eros Devishi for STAT STAT+ | Gene therapies for deafness dredge up an old question: Do deaf people want a 'cure'? As scientists celebrate gene therapy's ability to enable hearing, deaf people are feeling a familiar dread: Are we endangered? By Timmy Broderick The doctor would treat her sickle cell pain crisis — if she promised not to get an abortion Part 2 of "Coercive Care" looks at how a sickle cell patient's pregnancy was affected by living in a state with an abortion ban. By Eric Boodman Heat waves associated with increased risk of preterm birth in the U.S. A new study found correlations between extreme heat and early births in U.S. women. Heat impacts increase by age, education, minority status. By Annalisa Merelli STAT At Las Vegas conference, methadone clinics blast idea of doctors prescribing directly At an industry meeting, leaders of methadone clinics criticized attempts to open up access to this form of addiction treatment. By Lev Facher STAT+ | Airway disease drug from Insmed succeeds in one of the year's most anticipated trials The trial of the drug, called brensocatib, in a disease that causes airway problems has been one of the most closely watched this year. By Andrew Joseph STAT+ | Japanese conglomerate to buy Calliditas Therapeutics, maker of a kidney disease drug Calliditas, a Swedish biotech, has an approved drug called Tarpeyo that treats a rare kidney disease called IgA nephropathy. By Andrew Joseph Adobe Opinion: Achieving telehealth equity for people with hearing loss Captions are extremely helpful for people with hearing loss. So why aren't they regularly available during telehealth visits? By Zina Jawadi, Stephen McInturff, and Alexander Chern STAT+ | Merus drug, with immunotherapy, boosts tumor response in patients with head and neck cancer The Merus drug has generated attention, particularly from biotech investors, for its potential to improve head and neck cancer treatment. By Adam Feuerstein

More around STAT

Check out more exclusive coverage with a STAT+ subscription Read premium in-depth biotech, pharma, policy, and life science coverage and analysis with all of our STAT+ articles.

---

Enjoying Daily Recap? Tell us about your experience Continue reading the latest health & science news with the STAT app Download on the App Store or get it on Google Play

STAT, 1 Exchange Place, Boston, MA ©2024, All Rights Reserved. I no longer wish to receive STAT emails

Update Newsletter Preferences     •    Contact Us     •    Advertise with Us     •    View in Browser